![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Pharmaceutical Research Laboratory, Kirin Brewery Co., Gunma, Japan (H.O., Y.Y., T.W., M.Y., M.S., R.S., H.M., T.S., T.N.); Laboratory of Signal Transduction, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan (K.S., N.M., A.D., E.M., J.K., T.K., M.T., H.T., F.O.); Laboratory of Pharmacology, College of Pharmacy, Pusan National University, Busan, Republic of Korea (D.I.); and Department of Microbiology, Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Hokkaido, Japan (H.N., K.T.)
Lysophosphatidic acid (LPA) exerts a variety of biological responses through specific receptors: three subtypes of the EDG-family receptors, LPA1, LPA2, and LPA3 (formerly known as EDG-2, EDG-4, and EDG-7, respectively), and LPA4/GPR23, structurally distinct from the EDG-family receptors, have so far been identified. In the present study, we characterized the action mechanisms of 3-(4-[4-([1-(2-chlorophenyl)ethoxy]carbonyl amino)-3-methyl-5-isoxazolyl] benzylsulfanyl) propanoic acid (Ki16425) on the EDG-family LPA receptors. Ki16425 inhibited several responses specific to LPA, depending on the cell types, without any appreciable effect on the responses to other related lipid receptor agonists, including sphingosine 1-phosphate. With the cells overexpressing LPA1, LPA2, or LPA3, we examined the selectivity and mode of inhibition by Ki16425 against the LPA-induced actions and compared them with those of dioctyl glycerol pyrophosphate (DGPP 8:0), a recently identified antagonist for LPA receptors. Ki16425 inhibited the LPA-induced response in the decreasing order of LPA1 
LPA3 » LPA2, whereas DGPP 8:0 preferentially inhibited the LPA3-induced actions. Ki16425 inhibited LPA-induced guanosine 5'-O-(3-thio)triphosphate binding as well as LPA receptor binding to membrane fractions with a same pharmacological specificity as in intact cells. The difference in the inhibition profile of Ki16425 and DGPP 8:0 was exploited for the evaluation of receptor subtypes involved in responses to LPA in A431 cells. Finally, Ki16425 also inhibited LPA-induced long-term responses, including DNA synthesis and cell migration. In conclusion, Ki16425 selectively inhibits LPA receptor-mediated actions, especially through LPA1 and LPA3; therefore, it may be useful in evaluating the role of LPA and its receptor subtypes involved in biological actions.
Address correspondence to: Fumikazu Okajima, Ph.D., Laboratory of Signal Transduction, Institute for Molecular and Cellular Regulation, Gunma University, 3-39-15 Showa-machi, Maebashi 371-8512, Japan. E-mail: fokajima{at}showa.gunma-u.ac.jp
This article has been cited by other articles:
|
|
 |
|
  D. Shida, X. Fang, T. Kordula, K. Takabe, S. Lepine, S. E. Alvarez, S. Milstien, and S. Spiegel Cross-talk between LPA1 and Epidermal Growth Factor Receptors Mediates Up-regulation of Sphingosine Kinase 1 to Promote Gastric Cancer Cell Motility and Invasion Cancer Res., August 15, 2008; 68(16): 6569 - 6577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Steeg, C. E. Horak, and K. D. Miller Clinical-Translational Approaches to the Nm23-H1 Metastasis Suppressor Clin. Cancer Res., August 15, 2008; 14(16): 5006 - 5012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ishdorj, B. A. Graham, X. Hu, J. Chen, J. B. Johnston, X. Fang, and S. B. Gibson Lysophosphatidic Acid Protects Cancer Cells from Histone Deacetylase (HDAC) Inhibitor-induced Apoptosis through Activation of HDAC J. Biol. Chem., June 13, 2008; 283(24): 16818 - 16829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. Valentine, J. I. Fells, D. H. Perygin, S. Mujahid, K. Yokoyama, Y. Fujiwara, R. Tsukahara, J. R. Van Brocklyn, A. L. Parrill, and G. Tigyi Subtype-specific Residues Involved in Ligand Activation of the Endothelial Differentiation Gene Family Lysophosphatidic Acid Receptors J. Biol. Chem., May 2, 2008; 283(18): 12175 - 12187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-U. Chen, C.-H. Chou, H. Lee, C.-H. Ho, C.-W. Lin, and Y.-S. Yang Lysophosphatidic Acid Up-Regulates Expression of Interleukin-8 and -6 in Granulosa-Lutein Cells through Its Receptors and Nuclear Factor-{kappa}B Dependent Pathways: Implications for Angiogenesis of Corpus Luteum and Ovarian Hyperstimulation Syndrome J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 935 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gustin, E. Delaive, M. Dieu, D. Calay, and M. Raes Upregulation of Pentraxin-3 in Human Endothelial Cells After Lysophosphatidic Acid Exposure Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): 491 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Billon-Denis, Z. Tanfin, and P. Robin Role of lysophosphatidic acid in the regulation of uterine leiomyoma cell proliferation by phospholipase D and autotaxin J. Lipid Res., February 1, 2008; 49(2): 295 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Pradere, J. Klein, S. Gres, C. Guigne, E. Neau, P. Valet, D. Calise, J. Chun, J.-L. Bascands, J.-S. Saulnier-Blache, et al. LPA1 Receptor Activation Promotes Renal Interstitial Fibrosis J. Am. Soc. Nephrol., December 1, 2007; 18(12): 3110 - 3118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Shumay, J. Tao, H.-y. Wang, and C. C. Malbon Lysophosphatidic Acid Regulates Trafficking of beta2-Adrenergic Receptors: THE G{alpha}13/p115RhoGEF/JNK PATHWAY STIMULATES RECEPTOR INTERNALIZATION J. Biol. Chem., July 20, 2007; 282(29): 21529 - 21541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Chen, L. N. Towers, and K. L. O'Connor LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells Am J Physiol Cell Physiol, May 1, 2007; 292(5): C1927 - C1933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Damirin, H. Tomura, M. Komachi, J.-P. Liu, C. Mogi, M. Tobo, J.-Q. Wang, T. Kimura, A. Kuwabara, Y. Yamazaki, et al. Role of lipoprotein-associated lysophospholipids in migratory activity of coronary artery smooth muscle cells Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2513 - H2522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Zhang, Z. Liu, and K. E. Meier Lysophosphatidic acid as a mediator for proinflammatory agonists in a human corneal epithelial cell line Am J Physiol Cell Physiol, November 1, 2006; 291(5): C1089 - C1098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tanaka, S. Okudaira, Y. Kishi, R. Ohkawa, S. Iseki, M. Ota, S. Noji, Y. Yatomi, J. Aoki, and H. Arai Autotaxin Stabilizes Blood Vessels and Is Required for Embryonic Vasculature by Producing Lysophosphatidic Acid J. Biol. Chem., September 1, 2006; 281(35): 25822 - 25830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-W. Lee, R. Rivera, S. Gardell, A. E. Dubin, and J. Chun GPR92 as a New G12/13- and Gq-coupled Lysophosphatidic Acid Receptor That Increases cAMP, LPA5 J. Biol. Chem., August 18, 2006; 281(33): 23589 - 23597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Baker, Y. Fujiwara, K. R. Pigg, R. Tsukahara, S. Kobayashi, H. Murofushi, A. Uchiyama, K. Murakami-Murofushi, E. Koh, R. W. Bandle, et al. Carba Analogs of Cyclic Phosphatidic Acid Are Selective Inhibitors of Autotaxin and Cancer Cell Invasion and Metastasis J. Biol. Chem., August 11, 2006; 281(32): 22786 - 22793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kotarsky, A. Boketoft, J. Bristulf, N. E. Nilsson, A. Norberg, S. Hansson, C. Owman, R. Sillard, L. M. F. Leeb-Lundberg, and B. Olde Lysophosphatidic Acid Binds to and Activates GPR92, a G Protein-Coupled Receptor Highly Expressed in Gastrointestinal Lymphocytes J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 619 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Boucharaba, C.-M. Serre, J. Guglielmi, J.-C. Bordet, P. Clezardin, and O. Peyruchaud The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases PNAS, June 20, 2006; 103(25): 9643 - 9648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Lee, R. F. Swaby, Y. Liang, S. Yu, S. Liu, K. H. Lu, R. C. Bast Jr., G. B. Mills, and X. Fang Lysophosphatidic Acid Is a Major Regulator of Growth-Regulated Oncogene {alpha} in Ovarian Cancer. Cancer Res., March 1, 2006; 66(5): 2740 - 2748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Fujiwara, V. Sardar, A. Tokumura, D. Baker, K. Murakami-Murofushi, A. Parrill, and G. Tigyi Identification of Residues Responsible for Ligand Recognition and Regioisomeric Selectivity of Lysophosphatidic Acid Receptors Expressed in Mammalian Cells J. Biol. Chem., October 14, 2005; 280(41): 35038 - 35050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-Q. Wang, J. Kon, C. Mogi, M. Tobo, A. Damirin, K. Sato, M. Komachi, E. Malchinkhuu, N. Murata, T. Kimura, et al. TDAG8 Is a Proton-sensing and Psychosine-sensitive G-protein-coupled Receptor J. Biol. Chem., October 29, 2004; 279(44): 45626 - 45633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Anliker and J. Chun Lysophospholipid G Protein-coupled Receptors J. Biol. Chem., May 14, 2004; 279(20): 20555 - 20558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hama, J. Aoki, M. Fukaya, Y. Kishi, T. Sakai, R. Suzuki, H. Ohta, T. Yamori, M. Watanabe, J. Chun, et al. Lysophosphatidic Acid and Autotaxin Stimulate Cell Motility of Neoplastic and Non-neoplastic Cells through LPA1 J. Biol. Chem., April 23, 2004; 279(17): 17634 - 17639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-S. Im Discovery of new G protein-coupled receptors for lipid mediators J. Lipid Res., March 1, 2004; 45(3): 410 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yamada, K. Sato, M. Komachi, E. Malchinkhuu, M. Tobo, T. Kimura, A. Kuwabara, Y. Yanagita, T. Ikeya, Y. Tanahashi, et al. Lysophosphatidic Acid (LPA) in Malignant Ascites Stimulates Motility of Human Pancreatic Cancer Cells through LPA1 J. Biol. Chem., February 20, 2004; 279(8): 6595 - 6605. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
